{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:32:40Z","timestamp":1762342360941,"version":"build-2065373602"},"reference-count":13,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>We use this study to analyze the trends in in-hospital length of stay, total hospital charges, and mortality among adult patients with a primary diagnosis of adult-onset still\u2019s disease (AOSD). We used the 2016\u20132019 National Inpatient Sample (NIS) database to conduct a retrospective study on adult AOSD patients (\u226518 years old). We analyzed data on baseline patient and hospital characteristics and determined trends in in-hospital mortality, length of stay (LOS), and total hospital charges (TOTCHG). Univariate and multivariate linear and logistic regression analyses were performed to identify factors that independently affected these outcomes. Among the 1615 AOSD hospitalizations, the mean LOS was 7.34 days and the mean TOTCHG was 68,415.31 USD. Macrophage activating syndrome (MAS), disseminated intravascular coagulation (DIC), and a large hospital size were shown to statistically increase the LOS and TOTCHG, while a Native American background was shown to statistically decrease both. The mean in-hospital mortality was 0.929%, with age being the only independent predictor. Our findings reveal an increase in the economic burden of AOSD hospitalizations despite declining admissions and mortality rates. Complications, like MAS and DIC, were found to significantly contribute to this burden despite treatment advancements. Our study indicates the importance of investigating new strategies to prevent these complications.<\/jats:p>","DOI":"10.3390\/diseases12070166","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T12:20:38Z","timestamp":1721650838000},"page":"166","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mortality, Length of Stay and Cost of Hospitalization among Patients with Adult-Onset Still\u2019s Disease: Results from the National Inpatient Sample 2016\u20132019"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4398-1090","authenticated-orcid":false,"given":"Sushmita","family":"Mittal","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Missouri, Columbia, MO 65212, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2356-9784","authenticated-orcid":false,"given":"Benjamin","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Missouri, Columbia, MO 65212, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musaab","family":"Alfaki","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Missouri, Columbia, MO 65212, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"ref_1","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ard.54.7.587","article-title":"Epidemiology of adult Still\u2019s disease: Estimate of the incidence by a retrospective study in west France","volume":"54","author":"Billaud","year":"1995","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2019.04.004","article-title":"Racial\/Ethnic variations in morbidity and mortality in Adult-Onset Still\u2019s Disease: An analysis of national dataset","volume":"49","author":"Mehta","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","article-title":"Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3899\/jrheum.161286","article-title":"Application of the 2016 EULAR\/ACR\/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease","volume":"44","author":"Ahn","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_6","first-page":"41","article-title":"Adult onset Still\u2019s disease: Clinical presentation in a large cohort of Italian patients","volume":"28","author":"Franchini","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_7","first-page":"72","article-title":"Budget Impact Analysis of anakinra in the treatment of patients with Still\u2019s Disease","volume":"7","author":"Ravasio","year":"2020","journal-title":"Glob. Reg. Health Technol. Assess."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/art.27532","article-title":"Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still\u2019s disease","volume":"62","author":"Franchini","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/ket250","article-title":"Biologic treatments for adult-onset Still\u2019s disease","volume":"53","year":"2014","journal-title":"Rheumatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study","volume":"39","author":"Knight","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/14397595.2014.973659","article-title":"The effect of tocilizumab on preventing relapses in adult-onset Still\u2019s disease: A retrospective, single-center study","volume":"25","author":"Nishina","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Vitale, A., Caggiano, V., Maggio, M.C., Lopalco, G., Emmi, G., Sota, J., La Torre, F., Ruscitti, P., Bartoloni, E., and Conti, G. (2022). Canakinumab as first-line biological therapy in Still\u2019s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry. Front. Med., 9.","DOI":"10.1136\/annrheumdis-2023-eular.5540"},{"key":"ref_13","unstructured":"Hochberg, M.C. (2019). Adult-onset still disease. Rheumatology, Elsevier."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/7\/166\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:20:57Z","timestamp":1760109657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/7\/166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["diseases12070166"],"URL":"https:\/\/doi.org\/10.3390\/diseases12070166","relation":{},"ISSN":["2079-9721"],"issn-type":[{"type":"electronic","value":"2079-9721"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}